Ranibizumab is a monoclonal antibody fragment (Fab) which could inhibit angiogenesis via suppressing vascular endothelial growth factor (VEGF) A. In Dec. 2016, it was approved for the treatment of the age-related macular degeneration (AMD) and visual impairment caused by choroidal neovascularization (CNV).